Latest Breaking News On - Ablative solutions - Page 1 : vimarsana.com

Ablative Solutions TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation

/PRNewswire/ Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal.

United statesKate rumrillDavid kandzariAblative solutionsAmerican college of cardiologyScientific congressPiedmont heart institutePrnewswire ablative solutions incAblative solutions incLate breaking clinical trialPrimary endpointUncontrolled hypertensionTreatment armPivotal trialPeregrine systemAmerican college

Nerve ablation s varied outcomes in high blood pressure treatment

Nerve ablation s varied outcomes in high blood pressure treatment
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.

Davide kandzariAmerican college of cardiologyAblative solutionsPiedmont health care in atlantaAmerican college of cardiology annual scientific sessionPiedmont heart instituteDrug administrationAmerican collegeAnnual scientificPiedmont health carePeregrine system

Modest, mixed BP benefits seen with alcohol-mediated renal denervation: TARGET BP-1

Modest, mixed BP benefits seen with alcohol-mediated renal denervation: TARGET BP-1
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Davide kandzariKatie kalvaitisByregina schafferKeithc ferdinandPeregrine system kit ablative solutionsCardiovascular service line in atlantaPiedmont heart instituteAmerican college of cardiology scientific sessionAmerican collegeCardiology scientific sessionCardiovascular service lineRecor medicalPeregrine system kitAblative solutions

What to Know about the Aprocitentan Approval for Resistant Hypertension, with Michael Weber, MD

Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.

New yorkUnited statesAprocitentan tryvioMichael weberAblative solutionsCardiovascular medicineState universityStandard error

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial | Anticoagulation | JAMA

This randomized trial compares the effect of intermediate-dose vs standard prophylactic enoxaparin on a composite outcome of acute venous thromboembolism (VTE),

Virginia commonwealth universityUnited statesComunidad autonoma de catalunaUnited kingdomColumbia universityNew yorkKhorasane ra aviShahid beheshtiShahid modarresSistan va baluchestanAz arbayjane sharqiPooyesh darouSeyed hossein hosseiniHooman bakhshandehDavid jimenezMahdi yadollahzadeh